Latest Period
Q4 2025
Security Snapshot
CNS Pharmaceuticals, Inc. - Common Stock (CNSP) Institutional Ownership
CUSIP: 18978H508
13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025
Institutions Reporting
9
Shares (Excl. Options)
124,237
Price
$5.25
- Type / Class
- Equity / Common Stock
- Symbol
- CNSP on Nasdaq
- Shares outstanding
- 618,063
- Price per share
- $3.01
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 124,237
- Total reported value
- $652,245
- % of total 13F portfolios
- 0%
- Share change
- +99,621
- Value change
- +$522,895
- Number of holders
- 9
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CNSP - CNS Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 18978H508.
- 9 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 8 to 9 between Q3 2025 and Q4 2025.
- Reported value moved from $221,544 to $652,245.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Form 13F
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP 18978H508?
CUSIP 18978H508 identifies CNSP - CNS Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 18978H508:
Significant Owners of CNS Pharmaceuticals, Inc. - Common Stock (CNSP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 7.9% | +38% | $288,079 | +$97,981 | 48,827 | +52% | Stonepine Capital Management, LLC | 31 Dec 2025 |
As of 31 Dec 2025, 9 institutional investors reported holding 124,237 shares of CNS Pharmaceuticals, Inc. - Common Stock (CNSP). This represents 20% of the company’s total 618,063 outstanding shares.
Top 11 Institutional Shareholders
The largest institutional shareholders of CNS Pharmaceuticals, Inc. - Common Stock (CNSP) together control 20% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 7.9% | 48,827 | 0.2% | $256,342 | |
| Ikarian Capital, LLC | 7.4% | 45,830 | 0.03% | $240,608 | |
| DRW Securities, LLC | 2.5% | 15,429 | +9.8% | 0.01% | $81,002 |
| BOOTHBAY FUND MANAGEMENT, LLC | 2.2% | 13,524 | 0% | $71,001 | |
| UBS Group AG | 0.1% | 611 | -94% | 0% | $3,208 |
| BARRETT & COMPANY, INC. | 0% | 8 | 0% | 0% | $42 |
| BANK OF AMERICA CORP /DE/ | 0% | 4 | 0% | 0% | $21 |
| MAI Capital Management | 0% | 3 | 0% | 0% | $16 |
| DANSKE BANK A/S | 0% | 1 | 0% | 0% | $5 |
| CITIGROUP INC | 0% | 0 | -100% | $0 | |
| MORGAN STANLEY | 0% | 0 | -100% | $0 |